Temperature effect on the functional expression of human cytochromes P450 2A6 and 2E1 in Escherichia coli

Archives of Pharmacal Research

Volumn 28, Issue 4, 2005, Pages 433-437

  Yim, Sung Kun ^a   Ahn, Taeho ^a   Jung, Heung Chae ^b   Pan, Jae Gu ^b   Yun, Chul Ho ^a  

^a Chonnam National University   (South Korea)

^b GenoFocus Inc   (South Korea)

Author keywords

CYP Expression; Human CYP2A6; Human CYP2E1; Temperature effect

Indexed keywords

COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; CYP2F1 PROTEIN, HUMAN; CYTOCHROME P450; MIXED FUNCTION OXIDASE; RECOMBINANT PROTEIN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BIOSYNTHESIS; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; TEMPERATURE;

ARYL HYDROCARBON HYDROXYLASES; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; HUMANS; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; TEMPERATURE;

EID: 22844448749     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02977672     Document Type: Article

References (30)

1. Ahn, T., Yang, S., and Yun, C. H., Enhanced expression of human cytochrome P450 1A2 by co-expression with human molecular chaperone Hsp70. Toxicol. Lett., 153, 267-272 (2004a).
2. Ahn, T., Yang, S., and Yun, C. H., High-level expression of human cytochrome P450 1A2 by co-expression with human molecular chaperone HDJ-1(Hsp40). Protein Expr. Purif., 36, 48-52 (2004b).
3. Ahn, T. and Yun, C. H., High-level expression of human cytochrome P450 3A4 by co-expression with human molecular chaperone HDJ-1 (Hsp40). Arch. Pharm. Res., 27, 319-323 (2004).
4. Barnes, H. J., Arlotto, M. P., and Waterman, M. R., Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A., 88, 5597-5601 (1991).
5. Dong, M. S., Yamazaki, H., Guo, Z., and Guengerich, F. P., Recombinant human cytochrome P450 1A2 and an Nterminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys., 327, 11-19 (1996).
6. Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., Gyamfi, M. A., Sakurai, M., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., and Kamataki, T., Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis, (2004) (Aug. 12, web edition).
7. Gillam, E. M., Guo, Z., and Guengerich, F. P., Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch. Biochem. Biophys., 312, 59-66 (1994).
8. Guengerich, F. P. and Parikh, A., Expression of drug-metabolizing enzymes. Curr. Opin. Biotechnol., 8, 623-628 (1997).
9. Guengerich, F. P., Human cytochrome P450 enzymes. In Cytochrome P450, 2nd ed., P. R. Ortiz de Montelano, ed (New York: Plenum), pp. 473-535 (1995).
10. Guengerich, F. P., Kim, D. H., and Iwasaki, M., Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4, 168-179 (1991).
11. Hanna, I. H., Teiber, J. F., Kokones, K. L., and Hollenberg, P. F., Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch. Biochem. Biophys., 350, 324-332 (1998).
12. Inoue, E., Takahashi, Y., Imai, Y., and Kamataki, T., Development of bacterial expression system with high yield of CYP3A7, a human fetus-specific form of cytochrome P450. Biochem. Biophys. Res. Commun., 269, 623-627 (2000).
13. Iwata, H., Fujita, K., Kushida, H., Suzuki, A., Konno, Y., Nakamura, K., Fujino, A., and Kamataki, T., High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem. Pharmacol., 55, 1315-1325 (1998).
14. Lieber, C. S., Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev., 77, 517-544 (1997).
15. Omura, T. and Sato, R., The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J. Biol. Chem., 239, 2370-2378 (1964).
16. Oscarson, M., Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos., 29, 91-95 (2001).
17. Oyama, T., Kawamoto, T., Mizoue, T., Sugio, K., Kodama, Y., Mitsudomi, T., and Yasumoto, K., Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res., 17, 583-587 (1997).
18. Parikh, A. and Guengerich, F. P., Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein. Protein Expr. Purif., 9, 346-354 (1997).
19. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C. S., Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol., 3, 566-573 (1990).
20. Pritchard, M. P., Ossetian, R., Li, D. N., Henderson, C. J., Burchell, B., Wolf, C. R., and Friedberg, T., A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch. Biochem. Biophys., 345, 342-354 (1997).
21. Raucy, J. L., Schultz, E. D., Wester, M. R., Arora, S., Johnston, D. E., Omdahl, J. L., and Carpenter, S. P., Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab. Dispos., 25, 1429-1435 (1997).
22. Roberts, B. J., Shoaf, S. E., Jeong, K. S., and Song, B. J., Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less. Biochem. Biophys. Res. Commun., 205, 1064-1071 (1994).
23. Sandhu, P., Baba, T., and Guengerich, F. P., Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch. Biochem. Biophys., 306, 443-450 (1993).
24. Soucek, P., Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch. Biochem. Biophys., 370, 190-200 (1999).
25. Tricker, A. R., Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology, 183, 151-173 (2003).
26. Tsukino, H., Kuroda, Y., Qiu, D., Nakao, H., Imai, H., and Katoh, T., Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int. J. Cancer, 100, 425-428 (2002).
27. Wrighton, S. A. and Stevens, J. C., The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 22, 1-21 (1992).
28. Yamazaki, H., Inoue, K., Mimura, M., Oda, Y., Guengerich, F. P., and Shimada, T., 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem. Pharmacol., 51, 313-319 (1996).
29. Yamazaki, H., Inui, Y., Yun, C. H., Guengerich, F. P., and Shimada, T., Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789-1794 (1992).
30. Yun, C. H., Shimada, T., and Guengerich, F. P., Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol., 40, 679-685 (1991).